Received Oct 1, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Joint pain; Body ache; nausea; headache; patch of redness at the site; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of joint pain in a male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix with an associated reaction of injection site pain (1st dose received on an unknown date). On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced joint pain (Verbatim: Joint pain), general body pain (Verbatim: Body ache), nausea (Verbatim: nausea), headache (Verbatim: headache) and injection site erythema (Verbatim: patch of redness at the site). The outcome of the joint pain, general body pain, nausea, headache and injection site erythema were resolved (duration 48 hrs). It was unknown if the reporter considered the joint pain, general body pain, nausea, headache and injection site erythema to be related to Shingrix. It was unknown if the company considered the joint pain, general body pain, nausea, headache and injection site erythema to be related to Shingrix. Additional Information: GSK Receipt Date: 24-SEP-2025 The reporter stated be sure to plan on taking the day after getting the second shingles shot off. The patient was down all day with body, joint aches, nausea, headache. The patient had 5-inch patch of redness at the site. The next day of vaccination, 48 hours later, patient was fine.